Oncology Institute, Inc. (NASDAQ:STLN – Get Free Report) Director Brad Hively sold 298,853 shares of Oncology Institute stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $6.51, for a total transaction of $1,945,533.03. Following the transaction, the director directly owned 411,976 shares of the company’s stock, valued at approximately $2,681,963.76. This trade represents a 42.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oncology Institute Stock Up 4.1%
Shares of STLN opened at $6.56 on Thursday. Oncology Institute, Inc. has a fifty-two week low of $2.32 and a fifty-two week high of $7.05.
Oncology Institute (NASDAQ:STLN – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $161.28 million for the quarter, compared to analysts’ expectations of $152.80 million. Analysts predict that Oncology Institute, Inc. will post -0.21 earnings per share for the current year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
Separately, Weiss Ratings started coverage on Oncology Institute in a research note on Thursday, August 6th. They set a “sell (d-)” rating for the company. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.
Get Our Latest Analysis on Oncology Institute
Oncology Institute Company Profile
Oncology Institute is a physician-led healthcare company focused on delivering specialized cancer care through an integrated oncology platform. Its services are designed to support patients throughout the cancer-care journey, including diagnosis, treatment planning, chemotherapy and other medical oncology services, supportive care, and ongoing disease management.
The company’s business model emphasizes value-based oncology care, with care coordination and clinical programs intended to improve outcomes while managing the overall cost of treatment.
Featured Stories
- Five stocks we like better than Oncology Institute
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.
